AbbVie has joined the short list of big pharma companies that have taken a gamble on the emerging field of psychedelic medicines, paying $65 million on an option deal with startup Gilgamesh Pharma.
The two companies will work together on the development of a “next-generation” of psychedelic medicines for psychiatric disorders although – for now – the drugs themselves and the target indications are being kept under wraps.
